OKYO Key Statistics, Chart & Performance
The current stock price of OKYO is 2.04 USD. In the past month the price decreased by -0.94%. In the past year, price increased by 81.03%.
OKYO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.26 | 405.20B | ||
| AMGN | AMGEN INC | 15.17 | 178.67B | ||
| GILD | GILEAD SCIENCES INC | 15.4 | 156.51B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.51 | 116.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.5 | 82.78B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 793.57 | 53.47B | ||
| INSM | INSMED INC | N/A | 37.15B | ||
| NTRA | NATERA INC | N/A | 32.39B | ||
| BIIB | BIOGEN INC | 10.45 | 25.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.44 | 22.09B | ||
| INCY | INCYTE CORP | 15.65 | 19.73B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About OKYO
Company Profile
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Company Info
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London GB
Employees: 4
Phone: 442074952379
OKYO PHARMA LTD / OKYO FAQ
What does OKYO PHARMA LTD do?
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Can you provide the latest stock price for OKYO PHARMA LTD?
The current stock price of OKYO is 2.04 USD. The price decreased by -2.86% in the last trading session.
What is the dividend status of OKYO PHARMA LTD?
OKYO does not pay a dividend.
How is the ChartMill rating for OKYO PHARMA LTD?
OKYO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists OKYO stock?
OKYO stock is listed on the Nasdaq exchange.
OKYO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
OKYO Financial Highlights
Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 79.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.99% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OKYO Forecast & Estimates
8 analysts have analysed OKYO and the average price target is 8.5 USD. This implies a price increase of 316.67% is expected in the next year compared to the current price of 2.04.